Abeona Therapeutics Inc (ABEO) financials
Abeona Therapeutics revenue and earnings by year
Abeona Therapeutics's revenue was $5.82 million in the fiscal year to December 31, 2025, up 66.3% from the year before. Net income was $71.2 million, 1223.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 23.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 8 fiscal years
| Fiscal year to | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 4 | 1 | 3 | 10 | 3 | 1 | 1 |
| Revenue growth | 66.3% | 147.5% | -52.9% | -70.0% | 233.6% | 258.2% | -5.8% | — |
| Operating income | -88 | -46 | -50 | -90 | -81 | -58 | -28 | -24 |
| Operating margin | -1504.4% | -1300.9% | -3569.0% | -2994.5% | -814.2% | -1940.2% | -3325.7% | -2686.3% |
| Net income | 71 | -54 | -40 | -85 | -84 | -57 | -27 | -22 |
| Net margin | 1223.1% | -1548.2% | -2807.4% | -2831.2% | -842.3% | -1890.3% | -3263.9% | -2460.4% |
| Diluted EPS | $1.01 | -$2.53 | — | — | — | — | — | — |
| Free cash flow | -84 | -37 | -45 | -70 | -36 | -48 | -24 | -14 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ABEO in Markets.
See also: ABEO returns
No forecast, no recommendation. This page describes Abeona Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.